Condition: HER2 Insertion Mutation Positive Advanced NSCLC · Sponsor: Yongchang Zhang
The purpose of this study is to assess the safety and effectiveness of PD-1 Combined With Pyrotinib for First-line chemotherapy failed HER2 Insertion Mutation Positive Advanced Non-small Cell Lung Cancer
This description comes directly from the study's public registry record.
Yongchang Zhang, MD · +8613873123436 · zhangyongchang@csu.edu.cn
Xiangyu Zhang, PhD · 514775505@qq.com
Always discuss trial participation with your own doctor first.
| Hunan Provincal Tumor Hospital | Changsha, Hunan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04144569